Loading…
Remus Pharmaceuticals (REMUS)₹820.50+0.67%Pharmaceuticals
In the Mar 2026 quarter (consolidated), Remus Pharmaceuticals reported sales of ₹453 Cr, up 30.2% from Mar 2025, and net profit of ₹25.03 Cr, up 19.1% year on year. For the year to Mar 2026, sales were ₹853 Cr and net profit ₹46.05 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 28.99 | 185 | 273 | 348 | 400 | 453 |
| Expenses | 20.06 | 165 | 253 | 324 | 374 | 425 |
| Operating Profit | 8.97 | 19.94 | 19.94 | 24.91 | 26.92 | 29.90 |
| OPM % | 32.1% | 11.1% | 8.1% | 7.1% | 7.1% | 7.1% |
| Other Income | 2.01 | 3.01 | 3.01 | 3.01 | 3.01 | 4.01 |
| Interest | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 1.01 |
| Depreciation | 0.00 | 1.01 | 0.00 | 1.01 | 1.01 | 1.01 |
| Profit before tax | 9.98 | 21.96 | 21.96 | 24.96 | 27.97 | 30.94 |
| Tax % | 25.0% | 15.0% | 16.0% | 19.0% | 23.0% | 21.0% |
| Exceptional items | 0.00 | 1.81 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 6.01 | 19.03 | 19.03 | 21.02 | 22.04 | 25.03 |
| EPS (Rs) | 4.85 | 13.12 | 11.82 | 13.52 | 14.79 | 16.47 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 213 | 619 | 853 |
| Expenses | 184 | 577 | 799 |
| Operating Profit | 28.91 | 45.83 | 56.81 |
| OPM % | 14.1% | 7.1% | 7.1% |
| Other Income | 3.01 | 5.02 | 7.02 |
| Interest | 0.00 | 1.01 | 1.01 |
| Depreciation | 1.01 | 2.01 | 3.01 |
| Profit before tax | 29.94 | 46.92 | 58.89 |
| Tax % | 20.0% | 19.0% | 22.0% |
| Exceptional items | 0.00 | 0.17 | 0.00 |
| Net Profit | 24.03 | 38.03 | 46.05 |
| EPS (Rs) | 17.64 | 24.55 | 31.26 |
| Dividend payout % | 4.0% | 3.0% | 2.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 0.99 | 5.98 | 11.97 |
| Reserves | 156 | 251 | 340 |
| Borrowings | 14.01 | 23.01 | 27.04 |
| Other Liabilities | 161 | 154 | 201 |
| Total Liabilities | 334 | 434 | 580 |
| Fixed Assets | 13.98 | 15.98 | 17.97 |
| CWIP | 0.00 | 0.00 | 8.02 |
| Investments | 105 | 186 | 275 |
| Other Assets | 216 | 232 | 278 |
| Inventories | 43.10 | 52.09 | 72.15 |
| Trade receivables | 115 | 108 | 140 |
| Cash & equivalents | 14.04 | 8.03 | 13.03 |
| Total Assets | 334 | 434 | 580 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | 3.99 | 6.99 | 17.97 |
| Cash from investing activity | −8.98 | −10.97 | −14.95 |
| Cash from financing activity | 24.03 | 6.01 | 1.01 |
| Net cash flow | 18.99 | 2.99 | 4.99 |
| Capex | 0.71 | 3.99 | 14.55 |
| Free cash flow | 2.99 | 2.99 | 4.01 |
| CFO / OP % | 34.9% | 31.9% | 48.9% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 198 | 64 | 60 |
| Inventory days | 96 | 35 | 35 |
| Days payable | 208 | 48 | 36 |
| Cash conversion cycle | 84 | 49 | 57 |
| Working capital days | 98 | 54 | 57 |
| ROCE % | — | 20.0% | 17.1% |
For the Mar 2026 quarter, Remus Pharmaceuticals reported sales of ₹453 Cr, up 30.2% year on year and net profit of ₹25.03 Cr, up 19.1% year on year. The operating margin was 7.1%.
Remus Pharmaceuticals' sales for the year to Mar 2026 were ₹853 Cr.
Net profit for the year to Mar 2026 was ₹46.05 Cr. Earnings per share over the same trailing period were ₹31.26.
Remus Pharmaceuticals reported borrowings of ₹27.04 Cr at Mar 2026, against cash and equivalents of ₹13.03 Cr.
Cash from operations was ₹17.97 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹4.01 Cr.